| Literature DB >> 31379458 |
Slavica Dodig1, Ivana Čepelak1, Ivan Pavić2.
Abstract
The complex process of biological aging, as an intrinsic feature of living beings, is the result of genetic and, to a greater extent, environmental factors and time. For many of the changes taking place in the body during aging, three factors are important: inflammation, immune aging and senescence (cellular aging, biological aging). Senescence is an irreversible form of long-term cell-cycle arrest, caused by excessive intracellular or extracellular stress or damage. The purpose of this cell-cycles arrest is to limit the proliferation of damaged cells, to eliminate accumulated harmful factors and to disable potential malignant cell transformation. As the biological age does not have to be in accordance with the chronological age, it is important to find specific hallmarks and biomarkers that could objectively determine the rate of age of a person. These biomarkers might be a valuable measure of physiological, i.e. biological age. Biomarkers should meet several criteria. For example, they have to predict the rate of aging, monitor a basic process that underlies the aging process, be able to be tested repeatedly without harming the person. In addition, biomarkers have to be indicators of biological processes, pathogenic processes or pharmacological responses to therapeutic intervention. It is considered that the telomere length is the weak biomarker (with poor predictive accuracy), and there is currently no reliable biomarker that meets all the necessary criteria.Entities:
Keywords: aging; biomarkers; hallmarks; senescence
Mesh:
Substances:
Year: 2019 PMID: 31379458 PMCID: PMC6610675 DOI: 10.11613/BM.2019.030501
Source DB: PubMed Journal: Biochem Med (Zagreb) ISSN: 1330-0962 Impact factor: 2.313
Figure 1Overview of the process of senescence and its contribution to aging of entire organism (adapted according to references 5, 10 and 11). Based on kinetics of cell senescent processes there are two main categories of senescence – acute (programmed, transient) and chronic (not programmed, persistent) senescence. While acute senescence leads to embryonic development, wound healing and tissue repair of specific populations of cells and tissues, chronic senescence that is not directed towards specific cells leads into a stable cell-cycle arrest, a state that limits the proliferation of damaged cells. The main mediator of acute senescence is SASP. It seems that, because of age-related immunodeficiency or less production of proinflammatory SASP factors, immune cells becomes inefficiently in the elimination of senescent cells. p53, p16 and other tumour suppressor pathways mediators leads to senescence. Cancer development will occur if pre-senescent cells (stressed cells) would not been removed by specific mechanisms. However, it is not known which mechanisms are responsible for direction to senescence, apoptosis or to autophagy. Production of SASP factors may be inhibited by the use of: nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), interleukine 1α blockers, rapamycin, metformin; senescent cell killing may be induced by natural killer cells, T cell targeting, antibodies or antibody-mediated drug delivery. Early in life, senescent cells are transiently present and have a beneficial effect on development, homeostasis, and regeneration. However, at a later age, senescent cells accumulate and produce detrimental effects. ROS – reactive oxygen species. SASP – senescence-associated secretory phenotype. p53 – cellular tumour antigen p53. p21 – cyclin-dependent kinase inhibitor 1, cell-cycle inhibitor. p16 – cyclin-dependent kinase inhibitor 2A, multiple tumour suppressor 1.
Features of immune aging
| Neutrophils | Reduced phagocytosis and ROS production |
| Monocytes/Macrophages | Reduced phagocytosis, cytokine and chemokine secretion, reduced generation of NO and superoxide, reduced IFN-γ, inhibited response to growth factors |
| Dendritic Cells | Reduced phagocytosis and pinocytosis, increased IL-6 and TNF-α production, diminished TLR expression and function |
| Eosinophils | Reduced degranulation and superoxide production |
| Cytotoxic lymphocytes | |
| NK | Reduced numbers, increased reduced numbers, reduced cytotoxicity |
| NKT | Reduced proliferation |
| B cells | Decreased number, reduced proliferative capacity, increased oligoclonal expansion, reduced surface MHC class II molecule expression, reduced antibody avidity, increased concentration of IgG, IgA and concentration of autoantibodies |
| T cells | Reduced CD28 expression, accumulation of CD8+CD28- T cells, reduced TCR diversity, reduced signal transduction, reduced response and proliferation, increased differentiation of CD4+ into Th17 cells |
| Treg | Increased CD8+FOXP3+, decreased CD8+CD45RA+CCR7+ |
| ROS - reactive oxygen species. NO - nitric oxide. NK – natural killer cells. NKT – natural killer T cell. Treg – T-regulatory cells. TCR – T-cell receptor. IL – interleukine. IFN – interferon γ. TLR – toll-like receptor. TNF | |
Phenotypic and biochemical hallmarks of aging
| Anthropometry and physical function | BMI, waist circumference | I | |
| Facial features | Eye corner slope | D | |
| Nose width, Mouth width, Noise-mouth distance | I | ||
| Mouth width | I | ||
| Noise-mouth distance | I | ||
| Nutrient sensing | (S/P) Growth hormone and IGF-1 | D | |
| Protein metabolism | (S/P) Protein carbamylation, | I | |
| (Erc) Glycosated hemoglobin | I | ||
| (S/P) Advanced glycation end products N-glycans | I | ||
| Lipid metabolism | (S/P) Lipid profile, free fatty acids, isoprostanes | I | |
| Oxidative stress | (Erc) superoxide dismutase | D | |
| (Erc) glutathione, glutathione reductase, glutathione peroxidase | HD | ||
| Hormone, energy | (S/P) Triiodothyronine, cortisol | D | |
| Inflammation | (S/P) C-reactive protein, interleukin 6 | I | |
| Cardiovascular system | (S/P) troponin, natriuretic peptides, endothelin | I | |
| Lung | (S/P) surfactant protein D | I | |
| (arterial blood) partial pressure of oxygen | D | ||
| Kidney | (S/U) Glomerular filtration rate | D | |
| (S/P) creatinine, urea | I | ||
| Liver | (S/P) ALT, AST, GGT, albumin | D | |
| Reproductive function | (S/P) LH, FSH, DHEA | D | |
| Oxygen transport | (B) Htc, Hb, MCV, Rtc | D | |
| (S) erythropoietin, ferritin, hepcidin | D | ||
| Blood clotting | (S/P) D-dimers | I | |
| (B) platelet count | D | ||
| (Plt) platelet functions | I | ||
| (P) Fibrinogen | I | ||
| BMI – body mass index. IGF-1 – insulin-like growth factor 1, somatomedin C. S/P – serum/plasma. Erc – erythrocytes. S/U – serum/urine. B – blood. S – serum. P – plasma. ALT – alanine aminotransferase. AST – aspartate aminotransferase. GGT – gamma-glutamyl transferase. LH – luteinizing hormone. FSH – follicle-stimulating hormone. DHEA – dehydroepiandrosterone. Htc – haematocrit. Hb – haemoglobin. MCV – mean cell volume. Rtc – reticulocytes. I – increased. D – decreased. HD – increased in elderly hypertensive patients treated for their conditions. Adapted according to reference | |||
Laboratory methods used for determination of possible senescent-cell biomarkers
| morphological analysis | inverted phase-contrast microscope | 73 |
| cell viability | tetrazolium reduction, microplate spectrophotometer | 71 |
| SASP | ELISA | 12,68 |
| SAHF | immunohistochemistry | 12 |
| γH2AX | histochemistry | 12,68 |
| p16, p53, and p21 | histochemistry, immunohistochemistry | 12 |
| SA‐β‐GAL | histochemistry, immunohistochemistry, flow cytometry | 12,68,79 |
| autophagy | immunoblotting | 72 |
| cell proliferation | flow cytometry | 73 |
| leukocyte absolute telomere length | southern blot, PCR, FISH | 68,75,76 |
| ELISA – enzyme linked immunosorbent assay. SASP – senescence-associated secretory phenotype. SAHF – senescence-associated heterochromatin foci. γH2AX – a type of histone protein from the H2A family, a marker for activation of DNA damage response. PCR – polymerase chain reaction. p16 – cyclin-dependent kinase inhibitor 2A, multiple tumor suppressor 1. p53 – tumour suppressor gene, induces senescence growth arrest | ||